
Pennsylvania Battles Measles Surge, DST Ends Health Tips, Icosapent Ethyl Extends Liver Meta Survival, Ivonescimab Surpasses Durvalumab in Biliary Cancer, and more...
Shownotes
(0:10): Pennsylvania Battles Measles Outbreak: 1,200 Cases, 5 Deaths, Urges Community-Centered Vaccine Outreach
(1:52): Daylight Saving Time Ends: Tips to Ease Transition and Impact on Health Explored
(3:42): Icosapent Ethyl Boosts Survival in Liver Metastases Trial, ESMO 2026 Results Show
(6:25): Ivonescimab Shows Superior Survival in Biliary Cancer Phase 3 Trial, Outperforms Durvalumab Regimen
(9:17): New Immunotherapy Combo Slashes Recurrence and Death Rates in Bladder Cancer Trial
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: Wiss Now
(1:52): Daylight Saving Time Ends: Tips to Ease Transition and Impact on Health Explored
(3:42): Icosapent Ethyl Boosts Survival in Liver Metastases Trial, ESMO 2026 Results Show
(6:25): Ivonescimab Shows Superior Survival in Biliary Cancer Phase 3 Trial, Outperforms Durvalumab Regimen
(9:17): New Immunotherapy Combo Slashes Recurrence and Death Rates in Bladder Cancer Trial
To subscribe visit https://www.brief.news.
For more updates in your inbox each morning visit www.brief.news.
Image credit: Wiss Now